Literature DB >> 17116441

Antimicrobial therapy of Clostridium difficile-associated diarrhea.

Emilio Bouza1, Almudena Burillo, Patricia Muñoz.   

Abstract

Clostridium difficile-associated diarrhea (CDAD) is the most common etiologically-defined cause of hospital-acquired diarrhea. Caused by the toxins of certain strains of C difficile, CDAD represents a growing concern, with epidemic outbreaks in some hospitals where very aggressive and difficult-to-treat strains have recently been found. Incidence of CDAD varies ordinarily between 1 to 10 in every 1,000 admissions. Evidence shows that CDAD increases morbidity, length of stay, and costs. This article described the clinical manifestations of CDAD, related risk factors, considerations for confirming CDAD, antimicrobial and non-antimicrobial treatment of CDAD, and issues related to relapses. The article concludes with a discussion of recent epidemic outbreaks involving CDAD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17116441     DOI: 10.1016/j.mcna.2006.07.011

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  9 in total

1.  Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients.

Authors:  Carolyn D Alonso; Suzanne B Treadway; David B Hanna; Carol Ann Huff; Dionissios Neofytos; Karen C Carroll; Kieren A Marr
Journal:  Clin Infect Dis       Date:  2012-03-12       Impact factor: 9.079

2.  Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection.

Authors:  T Louie; M Miller; C Donskey; K Mullane; E J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

3.  Clostridium difficile infection after adult autologous stem cell transplantation: a multicenter study of epidemiology and risk factors.

Authors:  Carolyn D Alonso; Simon F Dufresne; David B Hanna; Annie-Claude Labbé; Suzanne B Treadway; Dionissios Neofytos; Sylvie Bélanger; Carol Ann Huff; Michel Laverdière; Kieren A Marr
Journal:  Biol Blood Marrow Transplant       Date:  2013-08-01       Impact factor: 5.742

4.  Management and prevention of recurrent clostridium difficile infection in patients after total joint arthroplasty: a review.

Authors:  Benjamin E Stein; William B Greenough; Simon C Mears
Journal:  Geriatr Orthop Surg Rehabil       Date:  2012-12

5.  Epidemiology, risk factors, and outcomes of Clostridium difficile infection in kidney transplant recipients.

Authors:  D Neofytos; K Kobayashi; C D Alonso; J Cady-Reh; D Lepley; M Harris; N Desai; E Kraus; A Subramanian; S Treadway; D Ostrander; C Thompson; K Marr
Journal:  Transpl Infect Dis       Date:  2012-11-23       Impact factor: 2.228

6.  Molecular Epidemiology of Clostridium difficile Infection in a Large Teaching Hospital in Thailand.

Authors:  Popchai Ngamskulrungroj; Sittinee Sanmee; Papanin Putsathit; Papanin Pusathit; Pipat Piewngam; Briony Elliott; Thomas V Riley; Pattarachai Kiratisin
Journal:  PLoS One       Date:  2015-05-22       Impact factor: 3.240

Review 7.  Vomiting, diarrhea, constipation, and gastroenteritis.

Authors:  Leila Getto; Eli Zeserson; Michael Breyer
Journal:  Emerg Med Clin North Am       Date:  2011-05       Impact factor: 2.264

8.  Evaluation of anti-infective-related Clostridium difficile-associated colitis using the Japanese Adverse Drug Event Report database.

Authors:  Satoshi Nakao; Shiori Hasegawa; Kazuyo Shimada; Ririka Mukai; Mizuki Tanaka; Kiyoka Matsumoto; Hiroaki Uranishi; Mayuko Masuta; Hiroaki Ikesue; Tohru Hashida; Kazuhiro Iguchi; Mitsuhiro Nakamura
Journal:  Int J Med Sci       Date:  2020-03-26       Impact factor: 3.738

9.  Reducing risk of Clostridium difficile infection and overall use of antibiotic in the outpatient treatment of urinary tract infection.

Authors:  Ivy Y Ge; Helene B Fevrier; Carol Conell; Malika N Kheraj; Alexander C Flint; Darvin S Smith; Lisa J Herrinton
Journal:  Ther Adv Urol       Date:  2018-06-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.